$HOWL

RA CAPITAL MANAGEMENT, L.P. sold $174K of HOWL (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 448,836 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.39 ($0.37–$0.40, $0.17M total) across 6 trades over 2026-06-12 to 2026-06-16.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jun 16, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HOWL
Neutral
medium confidence
Mentioned
$HOWL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HOWLNeutralLow
01

Why it matters

The newest concrete fact is the disclosed open-market sale size, price range, and post-transaction share count; it can influence short-term sentiment but does not introduce new operational or regulatory information.

02

Market read

Traders may monitor for follow-on selling/position changes, but the filing alone is unlikely to drive a durable repricing without accompanying fundamental catalysts.

03

What to watch

Because the trades occurred across multiple days and the filing is after the fact, the market may already have partially priced any immediate signal; also, indirect holdings can be less informative than direct insider sales.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-16 (after the June 12–16 sale window).

Background

The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics (HOWL), reported by RA Capital Management, L.P. as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$HOWLNeutralMedium confidence
Context

RA Capital Management, a 10% owner, sold 448,836 HOWL shares via open-market sales at $0.3700–$0.4000 in June 12–16.

Expected impact

Likely short-term sentiment drag; magnitude uncertain because it’s an ownership-structure/plan-driven transaction without new operating news.

Evidence & confidence

The filing is a primary-source insider/10%-owner transaction with a defined share count and price range, but it provides no new company-specific fundamentals (no guidance, trial, or deal).

Market effects

Limited sector read-through; this is a single-company ownership transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management under a 10b5-1-like process (though the filing states no pre-arranged plan), so it may not reflect a change in outlook.

Key entities

  • Werewolf Therapeutics, Inc.

    Subject of the Form 4 insider transaction; shares sold by a 10% owner via indirect holdings.

  • RA Capital Management, L.P.

    Reporter of the Form 4; sold 448,836 shares of HOWL at $0.3700–$0.4000.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HOWLHighAI 8/10

Latham & Watkins Advises on Oversubscribed US$150 Million Private Placement in Connection With Werewolf Therapeutics and Ambros Therapeutics’ Reverse Merger Transaction

Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal. The combined company will focus on Ambros' neridronate program for CRPS-1 and trade as AMBX. They secured $150M in private placement from healthcare investors. Latham & Watkins advised on the transaction.

$HOWLHighAI 8/10

Werewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.

$HOWLHighAI 8/10

Why is Werewolf Therapeutics stock surging more than 100% today?

Werewolf Therapeutics (HOWL) stock surged 114.1% after announcing an all-stock merger with Ambros Therapeutics, valued at $500M pre-financing. The combined entity will focus on Ambros's lead drug, neridronate, for Complex Regional Pain Syndrome. The deal includes a $150M private placement and is expected to close by Q1 2027. Werewolf also recently sold its technology platforms to Merck KGaA for up to $33M.